Acción STSA SATSUMA PHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Satsuma Pharmaceuticals, Inc.

Acciones

STSA

US80405P1075

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Satsuma Pharmaceuticals, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be presented at the American Headache Society's 65th Annual Scientific Meeting
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from NASDAQ Composite Index
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from S&P TMI Index
Insider Buy: Satsuma Pharmaceuticals
Satsuma Pharmaceuticals : Termination of Material Agreement - Form 8-K
Satsuma Pharmaceuticals, Inc. Announces CFO Changes
Satsuma Pharmaceuticals, Inc. Announces CEO Changes
Satsuma Pharmaceuticals, Inc. Announces Board Changes
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine Nasal Powder Product for the Acute Treatment of Migraine
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review
SATSUMA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc. Announces FDA Acceptance of 505(b)(2) New Drug Application for STS101
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Satsuma Pharmaceuticals, Inc. - STSA
SATSUMA PHARMACEUTICALS, INC. : Other Events (form 8-K)
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at the 75th American Academy of Neurology Annual Meeting
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción STSA
  4. Noticias Satsuma Pharmaceuticals, Inc.
  5. Otros idiomas